Actively Recruiting
Caspofungin for Pneumocystis Pneumonia in PLWHIV.
Led by Instituto Nacional de Enfermedades Respiratorias · Updated on 2024-11-19
60
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.
CONDITIONS
Official Title
Caspofungin for Pneumocystis Pneumonia in PLWHIV.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of probable or proven Pneumocystis jirovecii pneumonia (PCP) based on diagnostic classification
- Clinical, laboratory, and virological diagnostic studies completed at admission
You will not qualify if you...
- Treatment switch to caspofungin after day 7 of treatment initiation (only for group B)
- Development of additional opportunistic lung infections during hospitalization other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for Research in Infectious Diseases (CIENI)
Mexico City, Tlalpan, Mexico, 14080
Actively Recruiting
Research Team
X
Xavier Flores, MD
CONTACT
X
Xavier Flores, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here